BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34625423)

  • 1. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.
    Forshell LP; Li Y; Forshell TZ; Rudelius M; Nilsson L; Keller U; Nilsson J
    Oncotarget; 2011 Jun; 2(6):448-60. PubMed ID: 21646687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
    Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
    Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.
    Scialdone A; Khazaei S; Hasni MS; Lennartsson A; Gullberg U; Drott K
    Exp Hematol; 2019 Nov; 79():35-46.e1. PubMed ID: 31669559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
    Liu Z; He W; Gao J; Luo J; Huang X; Gao C
    Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.
    Schatz JH; Oricchio E; Wolfe AL; Jiang M; Linkov I; Maragulia J; Shi W; Zhang Z; Rajasekhar VK; Pagano NC; Porco JA; Teruya-Feldstein J; Rosen N; Zelenetz AD; Pelletier J; Wendel HG
    J Exp Med; 2011 Aug; 208(9):1799-807. PubMed ID: 21859846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
    Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ
    Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
    Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
    PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.
    Zhang JY; Zhang PP; Zhou WP; Yu JY; Yao ZH; Chu JF; Yao SN; Wang C; Lone W; Xia QX; Ma J; Yang SJ; Liu KD; Dong ZG; Guo YJ; Smith LM; McKeithan TW; Chan WC; Iqbal J; Liu YY
    Clin Cancer Res; 2019 Jul; 25(13):4168-4178. PubMed ID: 30824586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.